The effect of pneumoperitoneum on intraocular pressure in rabbits with alpha-chymotrypsin-induced glaucoma.
Increased intraperitoneal pressure is associated with physiological changes including alterations of intraocular pressure (IOP). We have previously shown that IOP is not adversely affected by increased intraperitoneal pressure up to 15 mm Hg in women with no preexisting eye disease. The aim of this study was to measure IOP changes associated with increased intraperitoneal pressure (up to 15 mm Hg) of 2 h duration in 12 rabbits with alpha-chymotrypsin-induced glaucoma. A reliable model of glaucoma was created by injecting alpha-chymotrypsin into the posterior chamber of the right eye in 12 rabbits. Thereafter, 5 of the 12 rabbits with glaucomatous eyes were treated with topical timolol. The left eye was used as a control. During pentobarbital general anesthesia, increased intraperitoneal pressure up to 15 mm Hg was created by intraperitoneal CO2 insufflation. Body temperature and expired CO2 were kept constant throughout the study. IOP measurements were made using an electronic pneumotonometer. IOP, mean arterial pressure, heart rate, and central venous pressure were recorded in head-up and head-down positions before, during, and after increased intraperitoneal pressure. The IOP of both eyes, in both treated and untreated rabbits, increased significantly from baseline only when increased intraperitoneal pressure associated with the head-down position resulted in a significant increase in central venous pressure. However, the IOP increase remained within the diurnal range. The major finding of this study is that, in a reliable model of glaucoma, CO2 pneumoperitoneum was associated with an increase in IOP when a head-down position was combined with pneumoperitoneum.


CONCLUSIONS
In rabbits with alpha-chymotrypsin-induced glaucoma, increased intraperitoneal pressure (up to 15 mm Hg) resulted in a significant intraocular pressure increase when pneumoperitoneum was associated with the head-down position. However, the intraocular pressure increase remained within the diurnal range.
Lentschener
C
C
Department of Anesthesiology, Hôpital Antoine Béclère, Clamart, France.
Leveque
J P
JP
Mazoit
J X
JX
Benhamou
D
D
D000759:Adjuvants, Anesthesia / Q000008:administration & dosage; D000287:Administration, Topical; D000768:Anesthesia, General; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D001831:Body Temperature; D002245:Carbon Dioxide / Q000008:administration & dosage / Q000378:metabolism; D002496:Central Venous Pressure / Q000502:physiology; D002918:Chymotrypsin / Q000009:adverse effects*; D004195:Disease Models, Animal; D005901:Glaucoma / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D018475:Head-Down Tilt; D006339:Heart Rate / Q000502:physiology; D007327:Insufflation; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D009798:Ocular Hypertension / Q000209:etiology / Q000503:physiopathology; D010424:Pentobarbital / Q000008:administration & dosage; D011028:Pneumoperitoneum, Artificial / Q000009:adverse effects; D011187:Posture; D011312:Pressure; D011817:Rabbits; D015203:Reproducibility of Results; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D014065:Tonometry, Ocular
D000759:Adjuvants, Anesthesia; D000959:Antihypertensive Agents; D002245:Carbon Dioxide; D013999:Timolol; D002918:Chymotrypsin; D010424:Pentobarbital